A new precision medicine initiative at the dawn of exascale computing.

ABSTRACT: Which signaling pathway and protein to select to mitigate the patient's expected drug resistance? The number of possibilities facing the physician is massive, and the drug combination should fit the patient status. Here, we briefly review current approaches and data and map an innovative patient-specific strategy to forecast drug resistance targets that centers on parallel (or redundant) proliferation pathways in specialized cells. It considers the availability of each protein in each pathway in the specific cell, its activating mutations, and the chromatin accessibility of its encoding gene. The construction of the resulting Proliferation Pathway Network Atlas will harness the emerging exascale computing and advanced artificial intelligence (AI) methods for therapeutic development. Mergin

SUBMITTER: Nussinov R 

PROVIDER: S-EPMC7785737 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature